AAIPharma, Inc.

Rentschler Biopharma, a global contract development and manufacturing organization (CDMO) will be increasing its production at its headquarters in Laupheim with the construction of a state-of-the-art buffer media station. The new four-story facility is slated to open by the end of 2027 and be fully operational by 2028. “The new buffer media facility at our Laupheim site in Germany will utilize high-precision automation systems, at par with industry standards in automation and digitalization. These will streamline production workflows, minimize manual intervention, and enhance data-driven decision-making through real-time monitoring and data analytics,” said Christiane Bardroff, Chief Operating Officer of Rentschler Biopharma. “We are also integrating digitalized processes for buffer and media preparation in enclosed environments, ensuring the highest levels of hygiene and safety. Additionally, predictive maintenance and real-time quality control will allow for proactive management, ultimately reducing downtime and enhancing process stability. Our vision is to create a connected facility that supports seamless data flows across the value chain.” The new facility will cover 3,400 square meters and include three media tanks and six buffer tanks. Rentschler’s investment in its construction, which a company representative confirmed to be in the high double-digit million range, is the largest single investment at the Laupheim site to date. Construction is expected to begin in the first quarter of 2025, and the facility is expected to be fully operational by 2028. googletag.cmd.push(function () { googletag.display('text-ad1'); }); Over the past few months, Rentschler Biopharma has announced expansions across its three sites in the US, UK and Germany. The company’s growth strategy is a response to the increasing global demand for biopharmaceutical products. “Our growth is fundamentally driven by the expanding and evolving needs of our clients and the biopharma industry for the development and manufacturing of biopharmaceuticals. As a CDMO, we see it as our responsibility to support our clients in transforming innovative ideas into life-saving biopharmaceuticals,” said Bardroff. “This commitment has led to substantial investments across our global sites: our new production line in Greater Boston enhances our US footprint; our expanded ATMP capabilities at our Stevenage, UK site, including lentiviral vector manufacturing, strengthen our ability to meet growing demand in advanced therapies; and now, our buffer media station at our headquarters in Laupheim, Germany, will further modernize and automate our infrastructure to meet rising client expectations.”

Welcome to Endpoints News ’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Lonza said it has extended a contract to produce monoclonal antibodies for an unnamed “major pharmaceutical partner.” If the asset is approved for commercialization, the CDMO will use its new facility in Visp, Switzerland, which is expected to finish construction this year, according to a Tuesday release. The partners’ original deal was signed in 2021. Lonza also said that its capsules and health ingredients division is not performing as well because of customers de-stocking hard capsule manufacturing. Nonetheless, the company said during its earnings call Thursday that it expects a “high level” number of contracts overall for 2024. Rentschler Biopharma announced on Thursday it is building a new 34,000 square meter facility at its headquarters in Laupheim, Germany. The factory’s construction will start in spring 2025 and will be fully operational by 2028. It will be used for manufacturing buffer solutions and other media. Siegfried’s new CEO Marcel Imwinkelried , who joined on Sept. 1, outlined his vision for the company on Thursday. It plans on focusing on commercial manufacturing as well as broadening its technology offerings for drug substance production, Imwinkelried said. Grifols has secured a new partnership with the Biomedical Advanced Research and Development Authority to test eye drops for mustard gas exposure, according to a Tuesday announcement. Radioisotope producer Actineer has manufactured the radioisotope actinium-225 for the first time, the company said Friday. Ac-225 will be available to customers by the middle of next year. Actineer is a joint venture between radiopharma company ITM and nuclear tech company Canadian Nuclear Laboratories. Sartorius reported a 2% decline in sales to $2.47 billion for its third quarter revenue last Thursday. This is compared to the $2.54 billion it reported in the same period last year. The drop is mainly attributed to its lab products and services division because of weak markets, especially in China.

Construction of a new buffer media facility in LaupheimLargest investment in the German site; project duration of approx. three yearsContinuous modernization, automation, and digitalization of the site LAUPHEIM, Germany, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), today announced the construction of a new state-of-the-art buffer media station at its company headquarters in Laupheim. The new facility aims to further increase production efficiency and modernize the site, ensuring that the evolving needs of clients and patients are anticipated and fully met, both now and in the future. “This investment underscores our commitment to the long-term development of our Laupheim site, a key part of Germany’s biotechnology landscape. This expansion will strengthen our competitive position in one of the world’s fastest-growing industries. As a company with 150 years of tradition, Rentschler Biopharma has always embraced forward-looking, strategic planning, enabling us to grow sustainably as an independent family-owned company. I would like to thank all colleagues involved in the planning and execution of this significant project,” said Benedikt von Braunmühl, Chief Executive Officer of Rentschler Biopharma. “Government support for a German national pharmaceutical strategy is an important signal for the industry as a whole. While our focus remains on strengthening global partnerships, this investment in our German site plays a crucial role in ensuring supply chain reliability and advancing our long-term growth strategy.” The state-of-the-art, four-story buffer media station, covering 34,000 square meters, is set to be operational by 2028. The new facility will be seamlessly integrated with the existing infrastructure, offering faster and more efficient processes, as well as ergonomically designed workstations, providing an optimal working environment for employees. The new building, along with all technical systems, will meet the highest quality and automation standards, and, through its state-of-the-art equipment, support Rentschler Biopharma's environmental and sustainability goals. “As a CDMO, it is our responsibility to support our clients in transforming innovative ideas into life-saving biopharmaceuticals. Patients with rare and severe diseases rely on the therapies we develop and manufacture in partnership with our clients. This project is therefore not just an investment in our infrastructure, it is a fundamental part of our work, creating value sustainably for the benefit of our clients and for patients and ensuring the availability of therapeutics in Germany and globally. With the new buffer media station, we are making a significant contribution to operational excellence, enabling us to respond rapidly to growing client demands. We are also creating a more ergonomic work environment for our employees and positioning our site for future success,” added Christiane Bardroff, Chief Operating Officer of Rentschler Biopharma. The new facility will include three media tanks and six buffer tanks, providing sufficient space and capacity for the production of buffer solutions and media. Buffer and media preparation will be carried out in separate areas to ensure the highest standards of hygiene and safety. In addition, the facility will be connected to the in-house logistics system and the piping system for upstream and downstream processes. Detailed planning for the new building has already begun, and construction is scheduled to start in spring 2025. Completion and operational launch are planned by the end of 2027, allowing the full potential of the new buffer media station to be realized by 2028. About Rentschler Biopharma SE Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company offers process development and manufacturing of biopharmaceuticals, including advanced therapies, as well as related consulting activities, project management and regulatory support. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. Rentschler Biopharma is a family-owned company with about 1,400 employees, headquartered in Laupheim, Germany, with operations in Milford, MA, USA and Stevenage, UK. In 2024, the company joined the United Nations Global Compact, emphasizing Rentschler Biopharma’s focus on sustainability. For further information about the company, please visit www.rentschler-biopharma.com. Follow Rentschler Biopharma on LinkedIn. Contact:Rentschler Biopharma SEDr. Latika Bhonsle-DeengGlobal Head of CommunicationsPhone: +49-7392-701-874communications@rentschler-biopharma.com Media inquiries: MC Services AGEva BauerPhone: +49-89-210228-0rentschler@mc-services.euU.S.Laurie DoylePhone: +1-339-832-0752 For high-resolution images, please contact communications@rentschler-biopharma.com.